(NASDAQ: VALN) Valneva Se's forecast annual revenue growth rate of 28.96% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 85.29%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.87%.
Valneva Se's revenue in 2025 is $228,288,372.On average, 1 Wall Street analysts forecast VALN's revenue for 2025 to be $35,217,457,226, with the lowest VALN revenue forecast at $35,217,457,226, and the highest VALN revenue forecast at $35,217,457,226. On average, 2 Wall Street analysts forecast VALN's revenue for 2026 to be $52,140,057,660, with the lowest VALN revenue forecast at $44,534,184,704, and the highest VALN revenue forecast at $59,745,930,616.
In 2027, VALN is forecast to generate $79,516,977,973 in revenue, with the lowest revenue forecast at $78,353,402,021 and the highest revenue forecast at $80,680,553,926.